Navigation Links
Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
Date:4/30/2013

CAMBRIDGE, Mass., April 30, 2013 /PRNewswire/ -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics™—a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins—announced today that Henri A. Termeer , Genzyme's retired chairman, president, and CEO, has joined Moderna's board of directors.

Over nearly 30 years at Genzyme, Termeer built one of the world's most innovative and commercially successful biotechnology companies. Under his leadership, Genzyme pioneered new models for sustainably bringing first-ever therapies to patients who were previously underserved. Termeer joins Moderna's board as the company embarks on the next phase of its growth strategy, strengthened by a strategic option agreement with AstraZeneca to develop new medicines for cardiometabolic diseases and by the continued progress of its preclinical programs in rare diseases and oncology.

"Messenger RNA therapeutics™ hold the same revolutionary potential as recombinant proteins did when they were first introduced nearly 30 years ago," said Noubar Afeyan , Chairman of Moderna's board and CEO of Flagship Ventures, the company's lead investor. "Henri's perspective will be invaluable as we work to deliver this new category of medicines for the treatment of serious diseases."

"It is an exciting time to be joining the board of Moderna, which I believe has the potential to transform the way in which protein therapeutics are developed, and to address diseases that are not currently reachable by recombinant technologies," Termeer said. "Moderna shares the same vision, ambition, and potential as many of the early biotechnology leaders. I look forward to helping the company deliver on its vast potential to improve the lives of patients across a wide array of disease areas."

"Henri has unparallel
'/>"/>

SOURCE Moderna Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. David Hooper Joins Evolution Marketing Research as Senior Director, Research
2. Full Service CRO DAaCRO Joins Salimetrics Center of Excellence Program
3. Jennifer C. Smith, DVM DACLAM, Formerly of Taconic Farms, Inc. Joins the Veterinary Bioscience Institute as the Vice President of Research and Development
4. Revolutionary new device joins world of smart electronics
5. Jerry Adams Joins VIC Technology Venture Development Board of Directors
6. Noted Atherosclerosis Researcher Joins AtheroNova Team
7. Foundation For the NIH Joins NIH In Seeking Proposals to Study Sports-Related Brain Injuries
8. Leo Gingras Joins Nutraceutical Innovations, LLC Board of Directors
9. Brian Cousins Joins Opedix Joint Support Athletic Wear as Vice President of Business Development
10. DuPont Joins Israel’s Office of the Chief Scientist Global Enterprise R&D Cooperation Framework
11. Nasseo Wins CONNECT Life Sciences Capital Competition and Joins CONNECT Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... CALGARY , June 30, 2015 /PRNewswire/ - ... ("Shareholders") of common shares of Resverlogix have approved ... to Eastern Capital Limited of 5,600,000 units at ... Private Placement"), each unit being comprised of one ... for aggregate proceeds of approximately CAD$15 million; and ...
(Date:6/30/2015)... 30, 2015  Today, Americord Registry, one of the fastest ... Horne , a partner at Kirkland & Ellis LLP, as ... Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We are thrilled ... says Martin Smithmyer , CEO of Americord. "He brings ... that will assist Americord,s growth and vision." ...
(Date:6/30/2015)... ... ... The maximum number of shares proposed to be purchased in the tender ... restricted stock). On June 29, 2015, the last trading day prior to the commencement ... OTCBB was $2.29 per share. , The tender offer will expire on July 28, ...
(Date:6/30/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... on the development of autologous cell therapies, announced today ... clinical trial of RCT-01, being tested for the ... enrolled and their tissue biopsy sent for processing ... of non-bulbar dermal sheath (NBDS) cells isolated from ...
Breaking Biology Technology:Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Americord Registry Announces Andrew Horne as Advisory Board Member 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4
... Roles as Vice Chairman of The Foundry and Advisor to ForSight ... ... Labs, MENLO PARK, Calif., Sept. 4 Morgenthaler Ventures, (http://www.morgenthaler.com/ventures ... technology investments, today announced the,addition of Hank Plain as partner in ...
... PRINCETON, N.J., Sept. 4 Medarex, Inc.,(Nasdaq: MEDX ... at the Bear,Stearns 20th Annual Healthcare Conference at 9:00 ... is being held at The Grand Hyatt,New York in ... and,will be available for replay through the Webcast page ...
... Paves the Way for the Phase III Clinical ... Commercialization of THR-100 in Developing ... NV (Euronext,Brussels: THR), a biotechnology company focused on ... technology transfer to Bharat,Biotech International Limited (Hyderabad, India) ...
Cached Biology Technology:Hank Plain Joins Morgenthaler Ventures as Partner 2Hank Plain Joins Morgenthaler Ventures as Partner 3Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference 2ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 2ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 3ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 4
(Date:6/24/2015)... Biometry authentication provider KeyLemon today announced ... one face in. Logo - ... in, entering the expanding biometric authentication market in ... answer to the password problem. With advanced face ... KeyLemon, one face in allows users to securely ...
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, ... and authentication solutions, today announced enhanced functionality of ... authentication solution.  The enhancements build on the ... the DigitalPersona Altus platform and provide expanded ... In today,s environment of increasing ...
(Date:6/17/2015)... , and HILDEN, Germany , June ... QGEN ; Frankfurt Prime Standard: QIA) today launched new Investigator ... in forensic laboratories in the United States ... to simultaneously analyze multiple key genomic markers (short tandem repeats ... Quality Sensor to evaluate the quality of DNA in ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... CITY While researching new ways to stop the ... Health Sciences Center, have discovered a compound that has ... appears in the journal Gene Regulation and Systems Biology. ... clinical trials, successfully stopped normal cells from turning into ...
... gel electrophoresis" Most teenagers wouldnt have a clue what ... Trigiano knows the protocol inside and out. When Andrew ... the University of Tennessee, was looking for an interesting ... differences in popular brands of Easter egg dyes, Trigianos ...
... will help archeologist Bill Middleton peer into the ancient ... hyperspectral data will help build the most accurate and ... state of Oaxaca, where the Zapotec people formed the ... you ask someone off the street about Mexican archeology, ...
Cached Biology News:Chemical compound prevents cancer in lab 2DNA fingerprinting simplified 2Archaeologist uses satellite imagery to explore ancient Mexico 2Archaeologist uses satellite imagery to explore ancient Mexico 3
Mouse Laminin-1 MAb (Clone AL-3)...
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
IEX-1 S/L (H-20)...
WIF-1 (N-20)...
Biology Products: